Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $43.71

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $43.71.

A number of equities analysts have commented on the company. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Royal Bank of Canada restated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Citigroup cut their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $15.07, for a total value of $774,974.75. Following the transaction, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. This represents a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 142,547 shares of company stock worth $1,764,709. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,628 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $49,000. Van ECK Associates Corp increased its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares in the last quarter. CWM LLC raised its stake in shares of Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after buying an additional 2,523 shares during the period. Finally, KBC Group NV boosted its position in shares of Arrowhead Pharmaceuticals by 40.8% in the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 2,132 shares during the period. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR traded up $0.40 on Tuesday, hitting $16.97. The company's stock had a trading volume of 1,266,897 shares, compared to its average volume of 1,524,301. The company has a 50-day simple moving average of $13.80 and a 200 day simple moving average of $17.32. The company has a market capitalization of $2.34 billion, a PE ratio of -3.28 and a beta of 0.96. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter in the previous year, the company posted ($1.02) earnings per share. Sell-side analysts forecast that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.